(Sharecast News) - Pfizer and BioNTech's Covid-19 vaccine candidate could be ready for use by the end of November, the boss of the former company, Albert Bourla, said.
In an open letter published on Friday, Pfizer's chief executive officer said he expected to have sufficient data available from the vaccine's clinical trials to ask regulators for emergency use approval by the third week of November.
The grant of an EUA by the Food and Drug Administration allows drugs and treatments to be deployed more quickly than would otherwise be the case when there is a public health emergency.
The two firms filed for EUA in Europe earlier in October.
As of 1519 BST, shares of Pfizer were adding 2.24% to $37.38 and those of BioNTech were up by 3.02% at $93.02.
(Adds latest statement)LONDON, May 15 (Reuters) - Santander told UK customers that all of its banking services were back up and running late on Saturday after technical problems stopped cash withdrawals and online account access for much of the da...